CClinicalTrials.gg
RecruitingNCT05990595ADLUpdated Aug 21, 2023

Evaluation of Health Effects of Adlay on Hyperlipidemia and Hyperglycemia Control

An interventional study of Adlay with white rice and white rice in Hyperlipidemia, Hyperglycemia and Type 2 Diabetes, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This study explores the efficacy of domestic adlay in improving blood sugar and lipids metabolism, cardiovascular function, and weight control in people with high blood pressure, hyperlipidemia, and hyperglycemia.

Through two weeks of cooked adlay-rice and white rice by a randomized cross-over design to evaluate the lipid- and glucose-lowering effects of adlay on patient with hyperlipidemia and/or hyperglycemia.

Read the detailed description

Evaluation of health effects of domestic adlay on lowering cholesterol and blood sugar

Hyperlipidemia and diabetes are major risk factors for cardiovascular disease. Clinical experiments have preliminarily proved that phytosterols can help lower blood lipids, and adlay is one of the domestic economic crops that has animal experimental evidence or theoretical potential to be beneficial to blood lipids and blood sugar control, which needs to be further explored and verified. This study explores the efficacy of domestic adlay in improving blood sugar and lipids metabolism, cardiovascular function, and weight control in people with high blood pressure, hyperlipidemia, and hyperglycemia.

We plan to recruit 60 patients with hyperglycemia or hyperlipidemia. aged between 20 and 80 years old, from National Taiwan University Hospital. This study is focused on high blood cholesterol, triglycerides, and hyperglycemia groups, thus participants must have higher cholesterol, triglycerides, or higher fasting blood glucose concentration even under currently stable treatment for at least 6 months. Lipid-lowering and hypoglycemic medication cannot be changed during this trial.

The clinical trial adopts a randomized cross-over trial, the experimental group to eat white rice with adlay and the control group to eat white rice. Participants in the project were randomly divided into two groups, group A and B, with 30 people in each group. Group A eat adlay to replace their carbohydrates: a box of 200 grams of rice (the amount of rice in dry weight is 36 grams of adlay and 54 grams of white rice) per day; Group B ate a box of 200 grams of white rice (the amount of rice was 87 grams based on dry weight) per day. After the first run of study, all participants resume to the original regular diet for two weeks, and then switch groups for crossover trial after the two-week washout period. In the experiment, during the crossover experiment, group A and group B replaced the experimental ingredients, that is, the original white rice group was replaced by adlay with white rice, and the original adlay and white rice group was replaced with white rice for a period of two weeks. To ensure that the test material is homogeneous and uniform, the white rice with adlay is made from the "cooked rice with adlay" produced by Nanqiao Group, HUACIANG INDUSTRY CO., LTD. The adlay cooked rice contains 40% adlay and Taichung No. 194 white rice 60%, and the control group used Taichung No. 194 white rice.

Every participant have to receive blood and urine sampling for biochemical measurement in each stage, 1. Baseline, 2. Two weeks after first stage: adlay with white rice or white rice, 3. Washed period stage for 2 weeks, 4. Two weeks after crossover stage. The main results analysis includes fasting blood sugar,glycosylated hemoglobin, glycosylated hemoglobin, triglycerides, total cholesterol, high-density cholesterol, and low-density cholesterol. Secondary outcome analysis includes blood pressure, body composition analysis, inflammation index, thyroid function, levels of intestinal hormones (cholecystokinin, gastrin) and glucagon-like peptide-1, and other emerging blood lipid indicators, such as small-dense LDL-C. The above measurements will be performed every 2 weeks for each stage. Pittsburgh Sleep Quality Index and Center for Epidemiological Studies Depression Scale (CES-D) will also be assessed every 2 weeks for each stage.

Keywords: hyperlipidemia, hyperglycemia, diabetes mellitus, randomized crossover trial

02

Conditions studied

  • Hyperlipidemia
  • Hyperglycemia
  • Type 2 Diabetes

Keywords

  • Adlay, Hyperlipidemia, Hyperglycemia
03

In context

Hyperglycemia

699 studies on the registry are indexed under Hyperglycemia; 105 are open to participants now.

This study's planned enrollment of 60 is above the median of 46 across 521 interventional studies indexed under Hyperglycemia.

Browse Hyperglycemia studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Hyperlipidemia: Levels of LDL-choleterol equal or greater than 130 mg/dL, or triglyceride equal or greater than 150 mg/dL
  2. Hyperglycemia: fasting glucose equal or greater than 100 mg/dL

Exclusion criteria

Exclusion Criteria:

Secondary hyperglycemia Secondary hyperlipidemia

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Adlay with white rice

    Group A eat cooked adlay with white rice to replace their carbohydrates: a box of 200 grams of adlay rice per day

    Dietary Supplement: Adlay with white rice

  • Placebo comparator
    White rice

    Group B ate a box of 200 grams of cooked white rice per day

    Dietary Supplement: white rice

Interventions

  • Dietary supplementAdlay with white rice

    We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.

  • Dietary supplementwhite rice

    white rice

06

What researchers measure

Primary outcomes

  1. Fasting blood glucose

    glucose-lowering effects

    Time frame: 2 weeks for each stage

  2. Cholesterol

    Lipids

    Time frame: 2 weeks for each stage

  3. HDL-cholesterol

    Lipids

    Time frame: 2 weeks for each stage

  4. LDL-cholesterol

    Lipids

    Time frame: 2 weeks for each stage

  5. Triglycerides

    Lipids

    Time frame: 2 weeks for each stage

  6. Glycosylated hemoglobin (HbA1C)

    Hemoglobin A1C is a form of hemoglobin (Hb) that is chemically linked to sugar

    Time frame: 2 weeks for each stage

Secondary outcomes

  1. Blood pressure

    physiological biomarkers

    Time frame: 2 weeks for each stage

  2. Body composition

    The percentages of fat, bone and muscle in human bodies by bioelectric impedance technology

    Time frame: 2 weeks for each stage

  3. hs-CRP (high sensitivity C-reactive protein)

    Inflammation

    Time frame: 2 weeks for each stage

  4. Free T4 and TSH (Thyroid Stimulating Hormone)

    Thyroid function tests

    Time frame: 2 weeks for each stage

  5. Insulin

    A peptide hormone produced by beta cells of the pancreatic islets

    Time frame: 2 weeks for each stage

  6. Gastrin, Cholecystokinine, and Glucagon-like peptide 1

    Intestin Hormones

    Time frame: 2 weeks for each stage

  7. Small-dense LDL-cholesterol

    LDL subpopulation particles

    Time frame: 2 weeks for each stage

Other outcomes

  1. Pittsburgh Sleep Quality Index

    Sleep quality assessment

    Time frame: 2 weeks for each stage

  2. Center for Epidemiologic Studies Depression Scale (CES-D), NIMH

    Depression scale assessment

    Time frame: 2 weeks for each stage

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
    • Ta-Chen Su, MD, PhD · Contact · tachensu@gmail.com · +886-972651062
    • Cheng-Yu Chiang, MSc · Contact · oldchiang@gmail.com · +886-965813735
    • Ta-Chen Su, MD, PhD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05990595
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Jul 7, 2023
Primary completion
Sep 28, 2023 (estimated)
Completion
Nov 30, 2023 (estimated)
Last update
Aug 21, 2023

Study contacts

Ta-Chen Su, MD, PhD
Contact
tachensu@gmail.com
+886-972651062
Cheng-Yu Chiang, MSc
Contact
oldchiang@gmail.com
+886-965813735
Ta-Chen Su, MD, PhD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion